Colorectal Cancer Roundtables
Advertisement
The panel concludes with an in-depth discussion on the evolving role of ctDNA in colorectal cancer management.
The panel highlights the BREAKWATER study and explores practical considerations for therapy before biomarker results.
The panel discusses strategies for IO in CRC, including the ATOMIC trial and adoption of neoadjuvant checkpoint inhibition.
The panel explores the evolving treatment landscape for patients with MSI-high metastatic colorectal cancer.
The panel dives into the role of biomarker testing in CRC, noting how next-gen sequencing and MSI testing are essential.
The panel concludes with the challenges of implementing cutting-edge research into colorectal cancer care and practice.
The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.
The panel expands on the incorporation of ctDNA in the CRC adjuvant setting, highlighting its prognostic value.
The panel details strategies for managing oligometastatic CRC, emphasizing the importance of a multidisciplinary approach.
The panel swaps opinions on advancements in EGFR and KRAS inhibitors, as well as the importance of NGS and liquid biopsy.
The panel focuses on the evolution of CRC treatment paradigms, including advances in chemo, biologic agents, and more.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.